TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is an increasingly common condition, strongly associated with the metabolic syndrome, that can lead to progressive hepatic fibrosis, cirrhosis and hepatic failure. Subtle inter-patient genetic variation and environmental factors combine to determine variation in disease progression. A common non-synonymous polymorphism in TM6SF2 (rs58542926 c.449 C>T, p.Glu167Lys) was recently associated with increased hepatic triglyceride content, but whether this variant promotes clinically relevant hepatic fibrosis is unknown. Here we confirm that TM6SF2 minor allele carriage is associated with NAFLD and is causally related to a previously reported chromosome 19 GWAS signal that was ascribed to the gene NCAN . Furthermore, using two histologically characterized cohorts encompassing steatosis, steatohepatitis, fibrosis and cirrhosis (combined n =1,074), we demonstrate a new association, independent of potential confounding factors (age, BMI, type 2 diabetes mellitus and PNPLA3 rs738409 genotype), with advanced hepatic fibrosis/cirrhosis. These findings establish new and important clinical relevance to TM6SF2 in NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The rs58542926 minor allele of transmembrane 6 superfamily member 2 (TM6SF2) is also reportedly associated with MASLD and sometimes MASH (134, 140-142).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [140]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Furthermore, the splice variant rs72613567 in the Hydroxysteroid 17-beta Dehydrogenase 13 (HSD17B13) gene has been identified as protective against MASH, with HSD17B13 potentially contributing to MASH fibrosis by promoting pyrimidine catabolism (134, 140-142).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [140]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PLINK: a tool set for whole-genome association and population-based linkage analyses.
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller, J., Sklar, P., de Bakker, P. I. W., Daly, M. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/519795 · Cited by 34,089
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Primary carcinoma of the liver.A study of 100 cases among 48,900 necropsies
Edmondson, H. A., & Steiner, P. E. (1954) · Cancer · doi:10.1002/1097-0142(195405)7:3<462::aid-cncr2820070308>3.0.co;2-e · Cited by 2,772
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302
Purcell, S., Cherny, S. S., & Sham, P. C. (2003) · Bioinformatics · doi:10.1093/bioinformatics/19.1.149 · Cited by 2,057
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
Anstee, Q. M., Targher, G., & Day, C. P. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.41 · Cited by 1,747
Self-citation
Cited by
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
“Recent genome-wide association studies have associated several genetic polymorphisms, notably PNPLA-3 variants, with SH and advanced fibrosis in patients with NAFLD.((112-121)) However, testing for these genetic variants in routine clinical care is currently not advocated.”
BackgroundGlobal burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
Self-citationEASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
Eslam, M., Sanyal, A. J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., Kleiner, D. E., Brunt, E., Bugianesi, E., Yki-Järvinen, H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.312 · Cited by 3,286
Self-citationThe multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
Buzzetti, E., Pinzani, M., & Tsochatzis, E. A. (2016) · Metabolism · doi:10.1016/j.metabol.2015.12.012 · Cited by 3,119
“[98] Liu YL, Reeves HL, Burt AD, et al.”
BackgroundAhlqvist, E., Storm, P., Käräjämäki, A., Martinell, M., Dorkhan, M., Carlsson, A., Vikman, P., Prasad, R. B., Aly, D. M., Almgren, P., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30051-2 · Cited by 2,335
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
Huang, D. Q., El-Serag, H. B., & Loomba, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00381-6 · Cited by 1,855
From NASH to HCC: current concepts and future challenges
Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O., & Heikenwalder, M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0145-7 · Cited by 1,392
Self-citationAdams, L. A., Anstee, Q. M., Tilg, H., & Targher, G. (2017) · Gut · doi:10.1136/gutjnl-2017-313884 · Cited by 1,174
Self-citationLiver fibrosis: Pathophysiology, pathogenetic targets and clinical issues
Parola, M., & Pinzani, M. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.09.002 · Cited by 1,160
Metabolism disrupting chemicals and metabolic disorders
Heindel, J. J., Blumberg, B., Cave, M., Machtinger, R., Mantovani, A., Mendez, M. A., Nadal, A., Palanza, P., Panzica, G., Sargis, R., et al. (2017) · Reproductive Toxicology · doi:10.1016/j.reprotox.2016.10.001 · Cited by 1,101
“located on chromosome 19 and associated with increased hepatic triglyceride content and lower serum lipoproteins [54, 55].”
McPherson, S., Hardy, T., Henderson, E., Burt, A. D., Day, C. P., & Anstee, Q. M. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.11.034 · Cited by 1,060
“This variability is in part due to subtle individual genetic differences that modify response to environmental factors and lifestyle, and so determine disease phenotype [14–16].”
BackgroundSelf-citationGenetics and epigenetics of NAFLD and NASH: Clinical impact
Eslam, M., Valenti, L., & Romeo, S. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.003 · Cited by 971
Triggering and resolution of inflammation in NASH
Schuster, S., Cabrera, D., Arrese, M., & Feldstein, A. E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0009-6 · Cited by 943
Nonalcoholic fatty liver disease
Brunt, E. M., Wong, V. W.-S., Nobili, V., Day, C. P., Sookoian, S., Maher, J. J., Bugianesi, E., Sirlin, C. B., Neuschwander-Tetri, B. A., & Rinella, M. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.80 · Cited by 818
Self-citationA Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease
Abul-Husn, N. S., Cheng, X., Li, A. H., Xin, Y., Schurmann, C., Stevis, P., Liu, Y., Kozlitina, J., Stender, S., Wood, G. C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712191 · Cited by 827
Self-citationNon-alcoholic fatty liver disease: An expanded review
Benedict, M., & Zhang, X. (2017) · World Journal of Hepatology · doi:10.4254/wjh.v9.i16.715 · Cited by 751
Clinical epidemiology and disease burden of nonalcoholic fatty liver disease
Perumpail, B. J., Khan, M. A., Yoo, E. R., Cholankeril, G., Kim, D., & Ahmed, A. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i47.8263 · Cited by 735
Mancina, R. M., Dongiovanni, P., Petta, S., Pingitore, P., Meroni, M., Rametta, R., Borén, J., Montalcini, T., Pujia, A., Wiklund, O., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.032 · Cited by 676
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), & European Association for the Study of Obesity (EASO) (2016) · Diabetologia · doi:10.1007/s00125-016-3902-y · Cited by 683
“Recently, the TM6SF2 gene has been reported as another disease modifier [15, 16] and may have clinical utility assisting risk stratification for liver-related vs cardiovascular morbidity.”
The Natural Course of Non-Alcoholic Fatty Liver Disease
Calzadilla Bertot, L., & Adams, L. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050774 · Cited by 620
Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum
Hardy, T., Oakley, F., Anstee, Q. M., & Day, C. P. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044224 · Cited by 611
“We have recently shown in two large histologically characterized cohorts (combined n = 1,074 patients) that when adjusted for age, sex, BMI, T2DM status, and PNPLA3 genotype, TM6SF2 rs58542926 and NCAN rs2228603 were both significantly associated with stage of fibrosis; the association with NCAN rs2228603 was lost whe…”
BackgroundSelf-citationGlobal Epidemiology and Genetics of Hepatocellular Carcinoma
Toh, M. R., Wong, E. Y. T., Wong, S. H., Ng, A. W. T., Loo, L.-H., Chow, P. K.-H., & Ngeow, J. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.01.033 · Cited by 583
Recent insights into the pathogenesis of nonalcoholic fatty liver disease
Arab, J. P., Arrese, M., & Trauner, M. (2018) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043617 · Cited by 573
Buch, S., Stickel, F., Trépo, E., Way, M., Herrmann, A., Nischalke, H. D., Brosch, M., Rosendahl, J., Berg, T., Ridinger, M., et al. (2015) · Nature Genetics · doi:10.1038/ng.3417 · Cited by 565
Francque, S. M., van der Graaff, D., & Kwanten, W. J. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.005 · Cited by 556
“TM6SF2 mutation [158] Catch-22 paradigm [162], opposite effects on lipid metabolism and therefore NAFLD and CVD Observation Link with NAFLD Potential mechanism”
BackgroundSelf-citationDongiovanni, P., Petta, S., Maglio, C., Fracanzani, A. L., Pipitone, R., Mozzi, E., Motta, B. M., Kaminska, D., Rametta, R., Grimaudo, S., et al. (2015) · Hepatology · doi:10.1002/hep.27490 · Cited by 533
Anstee, Q. M., Darlay, R., Cockell, S., Meroni, M., Govaere, O., Tiniakos, D., Burt, A. D., Bedossa, P., Palmer, J., Liu, Y.-L., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.003 · Cited by 499
“similar to those reported previously in candidate gene studies may reflect the complex nature of the histological disease phenotype[8, 11] and also limited statistical power.”
BackgroundResultSelf-citationEASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease
European Association for the Study of the Liver (EASL), E. A. F. T. S. O. D. (. (2016) · Obesity Facts · doi:10.1159/000443344 · Cited by 521
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Gastaldelli, A., & Cusi, K. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.07.002 · Cited by 455
“atherogenic lipids) and hepatic fibrosis progression.(88) Dongiovanni et al.”
BackgroundUpdate on NAFLD genetics: From new variants to the clinic
Trépo, E., & Valenti, L. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.02.020 · Cited by 393
Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease
Haas, J. T., Francque, S., & Staels, B. (2016) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021115-105331 · Cited by 394
Self-citationManagement of NAFLD: a stage-based approach
Rinella, M. E., & Sanyal, A. J. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.3 · Cited by 385
Azzu, V., Vacca, M., Virtue, S., Allison, M., & Vidal-Puig, A. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.12.054 · Cited by 369
Self-citationNonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment
Llovet, J. M., Willoughby, C. E., Singal, A. G., Greten, T. F., Heikenwälder, M., El-Serag, H. B., Finn, R. S., & Friedman, S. L. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00754-7 · Cited by 354
Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients
Leung, J. C., Loong, T. C., Wei, J. L., Wong, G. L., Chan, A. W., Choi, P. C., Shu, S. S., Chim, A. M., Chan, H. L., & Wong, V. W. (2017) · Hepatology · doi:10.1002/hep.28697 · Cited by 348
“395 Aspartate aminotransferase (IU/L) 28 (19-44) 25 (18-31) 32 (21-47) 0.”
ResultKim, D., & Kim, W. R. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.08.028 · Cited by 341
Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
Manne, V., Handa, P., & Kowdley, K. V. (2018) · Clinics in Liver Disease · doi:10.1016/j.cld.2017.08.007 · Cited by 335
“Additionally, mutations in another gene, known as the transmembrane 6 superfamily 2 (TM6SF2), have been linked to reduced hepatic TG secretion causing steatosis.(59,60) Apolipoprotein B-100 is a liver-specific protein that is critical for the assembly of VLDL.”
BackgroundNonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans
Pafili, K., & Roden, M. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101122 · Cited by 330
NAFLD in children: new genes, new diagnostic modalities and new drugs
Nobili, V., Alisi, A., Valenti, L., Miele, L., Feldstein, A. E., & Alkhouri, N. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0169-z · Cited by 309
Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease
Anstee, Q. M., Mantovani, A., Tilg, H., & Targher, G. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0010-0 · Cited by 310
Self-citationGenetic contributions to NAFLD: leveraging shared genetics to uncover systems biology
Eslam, M., & George, J. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0212-0 · Cited by 308
Recent insights on the role of cholesterol in non-alcoholic fatty liver disease
Arguello, G., Balboa, E., Arrese, M., & Zanlungo, S. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.05.015 · Cited by 306
Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors
Juanola, O., Martínez-López, S., Francés, R., & Gómez-Hurtado, I. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18105227 · Cited by 302
The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease
Fujii, H., Kawada, N., & Japan Study Group of NAFLD (JSG-NAFLD) (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113863 · Cited by 299
“E167K) polymorphism is an independent HCC risk factor is still controversial [103,111,112].”
BackgroundNon-alcoholic fatty liver disease: A patient guideline
Francque, S. M., Marchesini, G., Kautz, A., Walmsley, M., Dorner, R., Lazarus, J. V., Zelber-Sagi, S., Hallsworth, K., Busetto, L., Frühbeck, G., et al. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100322 · Cited by 264
Self-citationMBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals
Donati, B., Dongiovanni, P., Romeo, S., Meroni, M., McCain, M., Miele, L., Petta, S., Maier, S., Rosso, C., De Luca, L., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-04991-0 · Cited by 263
Self-citationGellert‐Kristensen, H., Richardson, T. G., Davey Smith, G., Nordestgaard, B. G., Tybjærg‐Hansen, A., & Stender, S. (2020) · Hepatology · doi:10.1002/hep.31238 · Cited by 252
“(11) For each of the three variants, individuals carrying two risk alleles have a 2-fold to 4-fold higher risk of developing fibrosis, cirrhosis, and HCC compared with those carrying zero risk alleles.(11-17) These relatively large effect sizes have spurred an interest in using the variants prognostically in fatty liv…”
BackgroundNon-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD
Tamaki, N., Ajmera, V., & Loomba, R. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00584-0 · Cited by 251
Genetic Factors That Affect Risk of Alcoholic and Nonalcoholic Fatty Liver Disease
Anstee, Q. M., Seth, D., & Day, C. P. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.037 · Cited by 254
Self-citationCausal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping
Liu, Z., Zhang, Y., Graham, S., Wang, X., Cai, D., Huang, M., Pique-Regi, R., Dong, X. C., Chen, Y. E., Willer, C., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.006 · Cited by 248
Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Lee, K.-C., Wu, P.-S., & Lin, H.-C. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0237 · Cited by 246
Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight
Eslam, M., El-Serag, H. B., Francque, S., Sarin, S. K., Wei, L., Bugianesi, E., & George, J. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00635-5 · Cited by 244
Self-citationClinical and Metabolic Characterization of Lean Caucasian Subjects With Non-alcoholic Fatty Liver
Feldman, A., Eder, S. K., Felder, T. K., Kedenko, L., Paulweber, B., Stadlmayr, A., Huber-Schönauer, U., Niederseer, D., Stickel, F., Auer, S., et al. (2017) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.318 · Cited by 239
Heyens, L. J. M., Busschots, D., Koek, G. H., Robaeys, G., & Francque, S. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.615978 · Cited by 234
“This specific gene variant has also been associated with fibrosis progression (113).”
BackgroundSelf-citationYounes, R., & Bugianesi, E. (2019) · Seminars in Liver Disease · doi:10.1055/s-0038-1677517 · Cited by 235
“Feng et al, 2014 8 Lean NAFLD have a more active and proin fl ammatory visceral adipose tissue Asian Wong et al, 2015 31 Waist circumference and triglyceride levels predicted the incidence of steatosis in lean individuals”
Non-alcoholic fatty liver disease and risk of cardiovascular disease
Lonardo, A., Sookoian, S., Pirola, C. J., & Targher, G. (2016) · Metabolism · doi:10.1016/j.metabol.2015.09.017 · Cited by 236
“Remarkably, there would not seem to be any interaction between the effect of the PNPLA3738409 and TM6SF2-rs58542926 variants on the risk of NAFLD [58,62,65]; hence, despite the TM6SF2-rs58542926 partly accounts for the missing heritability of the disease, so far the PNPLA3-”
BackgroundHepatic lipid droplets: A balancing act between energy storage and metabolic dysfunction in NAFLD
Mashek, D. G. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101115 · Cited by 232
Smagris, E., Gilyard, S., BasuRay, S., Cohen, J. C., & Hobbs, H. H. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.719955 · Cited by 226
Impact of non-invasive biomarkers on hepatology practice: past, present and future
Anstee, Q. M., Castera, L., & Loomba, R. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.03.026 · Cited by 224
Self-citationSookoian, S., Castaño, G. O., Scian, R., Mallardi, P., Fernández Gianotti, T., Burgueño, A. L., San Martino, J., & Pirola, C. J. (2015) · Hepatology · doi:10.1002/hep.27556 · Cited by 219
“observed that rs58542926 was significantly associated with histological fibrosis in the two explored cohorts of patients by adopting an additive model.(6) However, Wong et al.”
BackgroundMethodResultInfluentialGenetic predisposition in nonalcoholic fatty liver disease
Sookoian, S., & Pirola, C. J. (2017) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2016.0109 · Cited by 213
Molecular Pathogenesis of NASH
Caligiuri, A., Gentilini, A., & Marra, F. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091575 · Cited by 209
“160b ↑ NAFLD Human Biopsies Insulin signaling ? [30]”
BackgroundCaussy, C., Hsu, C., Lo, M., Liu, A., Bettencourt, R., Ajmera, V. H., Bassirian, S., Hooker, J., Sy, E., Richards, L., et al. (2018) · Hepatology · doi:10.1002/hep.29892 · Cited by 205
“(6,7) Although genome-wide association studies (GWAS) have identified genetic variants associated with NAFLD located on PNPLA3(8) and TM6SF2(9) genes, these common risk alleles do not account for all of the variance observed in NAFLD.”
BackgroundEpidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease
Makri, E., Goulas, A., & Polyzos, S. A. (2021) · Archives of Medical Research · doi:10.1016/j.arcmed.2020.11.010 · Cited by 204
Younes, R., Govaere, O., Petta, S., Miele, L., Tiniakos, D., Burt, A., David, E., Vecchio, F. M., Maggioni, M., Cabibi, D., et al. (2022) · Gut · doi:10.1136/gutjnl-2020-322564 · Cited by 205
“Although PNPLA3 genotype distribution did not significantly differ when comparing lean and non-lean patients, other variants, such those as TM6SF2, GCKR and MBOAT7 have not been investigated (28-30).”
BackgroundSelf-citationVujkovic, M., Ramdas, S., Lorenz, K. M., Guo, X., Darlay, R., Cordell, H. J., He, J., Gindin, Y., Chung, C., Myers, R. P., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01078-z · Cited by 205
Self-citationKrawczyk, M., Rau, M., Schattenberg, J. M., Bantel, H., Pathil, A., Demir, M., Kluwe, J., Boettler, T., Lammert, F., & Geier, A. (2017) · Journal of Lipid Research · doi:10.1194/jlr.p067454 · Cited by 204
“(11) reported that carriers of the minor allele are at risk of increased steatosis and fibrosis.”
BackgroundThe intersection between alcohol-related liver disease and nonalcoholic fatty liver disease
Díaz, L. A., Arab, J. P., Louvet, A., Bataller, R., & Arrese, M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00822-y · Cited by 207
Yu, J., Marsh, S., Hu, J., Feng, W., & Wu, C. (2016) · Gastroenterology Research and Practice · doi:10.1155/2016/2862173 · Cited by 199
Nonalcoholic fatty liver disease: Evolving paradigms
Lonardo, A., Nascimbeni, F., Maurantonio, M., Marrazzo, A., Rinaldi, L., & Adinolfi, L. E. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i36.6571 · Cited by 197
Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis—Literature Review
Ismaiel, A., & Dumitraşcu, D. L. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00202 · Cited by 192
Marchisello, S., Di Pino, A., Scicali, R., Urbano, F., Piro, S., Purrello, F., & Rabuazzo, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081948 · Cited by 190
Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease
Suresh, D., Srinivas, A. N., & Kumar, D. P. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.601710 · Cited by 186
“In addition, progressive alterations in Frontiers in Oncology | www.frontiersin.org 6 PNPLA3 and TM6SF2 genes, and micro RNA are known to promote steatosis, fibrosis, and cirrhosis in AFLD (110, 111).”
BackgroundAlcohol-Related Liver Disease: Basic Mechanisms and Clinical Perspectives
Liu, S.-Y., Tsai, I.-T., & Hsu, Y.-C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105170 · Cited by 183
Pathogenesis of MASLD and MASH – role of insulin resistance and lipotoxicity
Bansal, S. K., & Bansal, M. B. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17930 · Cited by 178
“When patients with biopsy-proven MASH were genotyped for the PNPLA3-rs738409 (minor allele: G), TM6SF2-rs58542926 (minor allele: T) and HSD17B13-rs72613567 (minor allele: TA) variants, it was found that the addition of these genetic markers into the prediction of advanced fibrosis (baseline model: age, sex, BMI, diabe…”
BackgroundInfluentialHa, S., Wong, V. W.-S., Zhang, X., & Yu, J. (2025) · Gut · doi:10.1136/gutjnl-2024-332398 · Cited by 181
“38 MBOAT7 encodes for an integral membrane protein that serves as a lyso-phosphatidylinositol acyltransferase to transfer polyunsaturated acyl-CoAs to lysophosphatidylinositol and other lysophospho-lipids in the Lands cycle.”
BackgroundMolecular mechanisms in MASLD/MASH-related HCC
Wang, X., Zhang, L., & Dong, B. (2025) · Hepatology · doi:10.1097/hep.0000000000000786 · Cited by 169
Nonalcoholic fatty liver disease and hepatocellular carcinoma
Zoller, H., & Tilg, H. (2016) · Metabolism · doi:10.1016/j.metabol.2016.01.010 · Cited by 174
Carlsson, B., Lindén, D., Brolén, G., Liljeblad, M., Bjursell, M., Romeo, S., & Loomba, R. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15738 · Cited by 169
Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research
Willebrords, J., Pereira, I. V. A., Maes, M., Crespo Yanguas, S., Colle, I., Van Den Bossche, B., Da Silva, T. C., de Oliveira, C. P. M. S., Andraus, W., Alves, V. A., et al. (2015) · Progress in Lipid Research · doi:10.1016/j.plipres.2015.05.002 · Cited by 171
“Recently, a single nucleotide polymorphism in transmembrane 6 superfamily member 2, a gene of unknown function on chromosome 19, has been linked to NAFLD [267].”
Pirola, C. J., & Sookoian, S. (2015) · Hepatology · doi:10.1002/hep.28142 · Cited by 172
“In fact, in one of these investigations, the investigators reported an association with liver fibrosis, but not histological degree of steatosis.(24) The rs58542926 C/T variant, located in chromosome 19:19268740, is a missense variant in which the nucleotide change from C to T in the forward strand results in an amino…”
BackgroundAjmera, V., Park, C. C., Caussy, C., Singh, S., Hernandez, C., Bettencourt, R., Hooker, J., Sy, E., Behling, C., Xu, R., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.04.014 · Cited by 166
Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis
Caussy, C., Soni, M., Cui, J., Bettencourt, R., Schork, N., Chen, C.-H., Ikhwan, M. A., Bassirian, S., Cepin, S., Gonzalez, M. P., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93465 · Cited by 166
“Liu YL, et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease.”
BackgroundInsights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases
Yu, Y., Cai, J., She, Z., & Li, H. (2019) · Advanced Science · doi:10.1002/advs.201801585 · Cited by 164
Perakakis, N., Stefanakis, K., & Mantzoros, C. S. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154320 · Cited by 162
“92) [35] and adjusted models for age, sex, obesity and diabetes, or fibrosis (OR = 1.”
The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2
Day, C., & Anstee, Q. (2015) · Seminars in Liver Disease · doi:10.1055/s-0035-1562947 · Cited by 161
Self-citationEmdin, C. A., Haas, M. E., Khera, A. V., Aragam, K., Chaffin, M., Klarin, D., Hindy, G., Jiang, L., Wei, W.-Q., Feng, Q., et al. (2020) · PLOS Genetics · doi:10.1371/journal.pgen.1008629 · Cited by 161
Boyle, M., Masson, S., & Anstee, Q. M. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.006 · Cited by 159
“[52, 53] and ALD [48], but is protective against dyslipidaemia and cardiovascular disease [54-56].”
BackgroundSelf-citationLi, B., Zhang, C., & Zhan, Y.-T. (2018) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2018/2784537 · Cited by 159
“Glu167Lys) was associated with increased risk for advanced fibrosis independent of gender, age at biopsy, BMI, T2DM, and PNPLA3 rs738409 genotype [30].”
BackgroundFound in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH)
Wang, S., & Friedman, S. L. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adi0759 · Cited by 158
“The rs58542926 minor allele of transmembrane 6 superfamily member 2 ( TM6SF2) is also reportedly associated with MASLD and some-times MASH ( 133 , 139 – 141 ).”
BackgroundGenetic and epigenetic factors determining NAFLD risk
Jonas, W., & Schürmann, A. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101111 · Cited by 176
Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016
Kaswala, D. H., Lai, M., & Afdhal, N. H. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4079-4 · Cited by 162
Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis
Dongiovanni, P., Romeo, S., & Valenti, L. V. C. (2015) · BioMed Research International · doi:10.1155/2015/460190 · Cited by 155
TM6SF2: A Novel Genetic Player in Nonalcoholic Fatty Liver and Cardiovascular Disease
Luo, F., Oldoni, F., & Das, A. (2021) · Hepatology Communications · doi:10.1002/hep4.1822 · Cited by 172
Bidirectional Relationships and Disconnects between NAFLD and Features of the Metabolic Syndrome
Wainwright, P., & Byrne, C. D. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030367 · Cited by 162
“A further study of 1074 individuals demonstrated an association between this variant and advanced fibrosis and cirrhosis that occurred independently of potential confounding factors such as age, BMI, presence of type 2 diabetes and PNPLA3 genotype status [87].”
BackgroundFougerat, A., Montagner, A., Loiseau, N., Guillou, H., & Wahli, W. (2020) · Cells · doi:10.3390/cells9071638 · Cited by 156
Goffredo, M., Caprio, S., Feldstein, A. E., D’Adamo, E., Shaw, M. M., Pierpont, B. M., Savoye, M., Zhao, H., Bale, A. E., & Santoro, N. (2015) · Hepatology · doi:10.1002/hep.28283 · Cited by 144
Nonalcoholic Fatty Liver Disease and Type 2 Diabetes: Common Pathophysiologic Mechanisms
Saponaro, C., Gaggini, M., & Gastaldelli, A. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0607-4 · Cited by 155
Non-alcoholic fatty liver disease and risk of type 2 diabetes
Lallukka, S., & Yki‐Järvinen, H. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.06.006 · Cited by 146
Metadata
- Authors
- Liu, Y.-L., Reeves, H. L., Burt, A. D., Tiniakos, D., McPherson, S., Leathart, J. B. S., Allison, M. E. D., Alexander, G. J., Piguet, A.-C., Anty, R., Donaldson, P., Aithal, G. P., Francque, S., Van Gaal, L., Clement, K., Ratziu, V., Dufour, J.-F., Day, C. P., Daly, A. K., & Anstee, Q. M.
- Affiliations
- Newcastle University (GB)
- Addenbrooke's Hospital (GB)
- University Hospital of Bern (CH)
- Inserm (FR)
- Nottingham University Hospitals NHS Trust (GB)
- Antwerp University Hospital (BE)
- Pitié-Salpêtrière Hospital (FR)
- Corresponding author
- Anstee, Quentin M.
- ORCID
- Venue
- Nature Communications
- Published
- 2014-06-30
- Volume
- 5
- Issue
- 1
- Pages
- 4309-4309
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4279183
- OpenAlex
- W2038831349
- Cited by
- 623
- References
- 45
- Citations by year
- 2026: 22 · 2025: 42 · 2024: 50 · 2023: 51 · 2022: 56 · 2021: 61 · 2020: 82 · 2019: 49 · 2018: 50 · 2017: 45 · 2016: 54 · 2015: 50 · 2014: 11
- FWCI
- 40.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Bern Open Repository and Information System (University of Bern) (submittedVersion, cc-by)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, cc-by)
- Newcastle University ePrints (Newcastle Univesity) (cc-by)
- Open Access CRIS of the University of Bern
- Funders
- National Institute for Health and Care Research (FP7/2007–2013)
- European Commission (2007–2013, FP7 2007-2013, FP7/2007, 241762)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- TM6SF2, rs58542926, non-alcoholic fatty liver disease, liver fibrosis, liver cirrhosis, non-synonymous polymorphisms, genetic association, hepatic triglyceride content, neurocan, chromosome 19, steatohepatitis, PNPLA3, disease progression
- MeSH terms
- Adult, Aged, Alleles, Female, Genotype, Heterozygote, Humans, Liver, Liver Cirrhosis, Male, Membrane Proteins, Middle Aged, Nerve Tissue Proteins, Chondroitin Sulfate Proteoglycans, Cohort Studies, Disease Progression, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, Lectins, C-Type, Neurocan, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.